FY2026 Earnings Forecast for ONCY Issued By Zacks Research

Oncolytics Biotech Inc. (NASDAQ:ONCY) – Equities research analysts at Zacks Research issued their FY2026 earnings estimates for shares of Oncolytics Biotech in a report issued on Tuesday, April 7th. Zacks Research analyst D. Bautz anticipates that the company will post earnings per share of ($0.24) for the year. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.28) per share. Zacks Research also issued estimates for Oncolytics Biotech’s FY2027 earnings at ($0.23) EPS and FY2028 earnings at ($0.21) EPS.

Oncolytics Biotech (NASDAQ:ONCY) last posted its quarterly earnings data on Monday, March 30th. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02).

Other analysts have also issued reports about the stock. Wall Street Zen upgraded shares of Oncolytics Biotech from a “strong sell” rating to a “hold” rating in a research note on Saturday, April 4th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Oncolytics Biotech in a research note on Friday, March 27th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $8.50.

Oncolytics Biotech Trading Up 0.7%

ONCY stock opened at $0.91 on Wednesday. The company has a market capitalization of $105.20 million, a PE ratio of -3.12 and a beta of 0.98. Oncolytics Biotech has a 12-month low of $0.33 and a 12-month high of $1.51. The business’s fifty day moving average price is $0.97 and its 200 day moving average price is $1.05.

Institutional Investors Weigh In On Oncolytics Biotech

Large investors have recently bought and sold shares of the stock. Scientech Research LLC purchased a new stake in Oncolytics Biotech during the 3rd quarter worth about $25,000. Blair William & Co. IL purchased a new stake in shares of Oncolytics Biotech in the fourth quarter valued at about $28,000. Security National Bank of Sioux City Iowa IA purchased a new stake in shares of Oncolytics Biotech in the fourth quarter valued at about $29,000. Ground Swell Capital LLC purchased a new stake in shares of Oncolytics Biotech in the fourth quarter valued at about $30,000. Finally, CIBC Private Wealth Group LLC purchased a new stake in shares of Oncolytics Biotech in the fourth quarter valued at about $44,000. Hedge funds and other institutional investors own 6.82% of the company’s stock.

Insider Buying and Selling at Oncolytics Biotech

In other Oncolytics Biotech news, Director Patricia S. Andrews purchased 35,400 shares of the firm’s stock in a transaction on Thursday, February 12th. The stock was bought at an average price of $0.86 per share, with a total value of $30,444.00. Following the transaction, the director directly owned 78,128 shares of the company’s stock, valued at approximately $67,190.08. This represents a 82.85% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Andrew Aromando purchased 29,600 shares of the firm’s stock in a transaction on Wednesday, February 11th. The stock was acquired at an average cost of $0.86 per share, with a total value of $25,456.00. Following the transaction, the insider directly owned 55,100 shares in the company, valued at $47,386. This trade represents a 116.08% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders purchased 404,282 shares of company stock worth $363,232. 0.10% of the stock is currently owned by corporate insiders.

About Oncolytics Biotech

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.